An analysis from the FLEX study showed that only patients in MammaPrint's highest risk category benefitted from the addition ...

Geopolitical tensions with the US and the allure of cheaper and quicker trials are drawing Chinese biotechs developing ...

The firm's newly launched Cas-CLEAR platform uses Cas12a2 nucleases to recognize and kill cancer cells expressing certain genetic signatures.

The company is trying again after receiving a complete response letter from the FDA last year requested more data.

The drugmaker made its decision after reviewing clinical and non-clinical studies, and said it's committed to exploring other treatment approaches.

The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.

NEW YORK – Fore Biotherapeutics on Tuesday closed an upsized Series D-2 funding round extension, raising $67.4 million for advancing a BRAF inhibitor in its pipeline. The financing was led by SR One, ...

Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...

The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...